These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 20941539

  • 1. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM.
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [Abstract] [Full Text] [Related]

  • 2. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
    Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JM.
    Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
    [Abstract] [Full Text] [Related]

  • 3. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

  • 4. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep 01; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 5. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, Groh N, Polier A, Brandt I, Lotz L, Hoffmann I, Koppitz F, Oeser S, Mueller A, Fasching PA, Lux MP, Beckmann MW, Schrauder MG.
    Biochem Pharmacol; 2012 Feb 15; 83(4):480-8. PubMed ID: 22142888
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 7. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 8. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May 05; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

  • 9. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A, Inoue N, Yagi T, Nishimukai A, Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe T, Hirota S, Sasa M, Katagiri T, Miyoshi Y.
    Clin Breast Cancer; 2015 Jun 05; 15(3):197-203. PubMed ID: 25600244
    [Abstract] [Full Text] [Related]

  • 10. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O, Wackwitz B, Haus U, Ortmann O.
    Gynecol Oncol; 2006 Aug 05; 102(2):292-9. PubMed ID: 16443261
    [Abstract] [Full Text] [Related]

  • 11. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.
    De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, Hursting SD.
    Mol Carcinog; 2013 Jun 05; 52(6):446-58. PubMed ID: 22290600
    [Abstract] [Full Text] [Related]

  • 12. Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.
    Advani AS, Mahfouz RZ, Maciejewski J, Rybicki L, Sekeres M, Tripp B, Kalaycio M, Bates J, Saunthararajah Y.
    Clin Lymphoma Myeloma Leuk; 2014 Apr 05; 14(2):172-177.e1. PubMed ID: 24332215
    [Abstract] [Full Text] [Related]

  • 13. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A, Dalino P, Salahuddin N, Korbonits M, Grossman AB.
    Neuroendocrinology; 2008 Apr 05; 87(3):168-81. PubMed ID: 18025810
    [Abstract] [Full Text] [Related]

  • 14. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.
    Clin Cancer Res; 2005 Jul 15; 11(14):5319-28. PubMed ID: 16033851
    [Abstract] [Full Text] [Related]

  • 15. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2010 Apr 15; 23(4):1167-72. PubMed ID: 20204306
    [Abstract] [Full Text] [Related]

  • 16. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA, Lebwohl D.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [Abstract] [Full Text] [Related]

  • 17. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.
    Clin Cancer Res; 2004 Oct 15; 10(20):6779-88. PubMed ID: 15501954
    [Abstract] [Full Text] [Related]

  • 18. Everolimus: a new hope for patients with breast cancer.
    Sendur MA, Zengin N, Aksoy S, Altundag K.
    Curr Med Res Opin; 2014 Jan 15; 30(1):75-87. PubMed ID: 24050600
    [Abstract] [Full Text] [Related]

  • 19. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
    Malaguti P, Vari S, Cognetti F, Fabi A.
    Anticancer Res; 2013 Jan 15; 33(1):21-8. PubMed ID: 23267124
    [Abstract] [Full Text] [Related]

  • 20. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
    Yu J, Henske EP.
    Cancer Res; 2006 Oct 01; 66(19):9461-6. PubMed ID: 17018601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.